A Phase 1 clinical trial involving thymosin alpha-1 was updated on July 16, 2026. The study, registered as NCT06821100, is titled "Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine."
The trial is currently listed with a status of recruiting. It is designated as a Phase 1 study, indicating an early stage of clinical investigation.
According to the registration, the trial focuses on older adults who are receiving booster doses of COVID-19 vaccine. The study aims to examine thymalfasin, also known as Thymosin Alpha 1, in this population.
Thymosin alpha-1 remains classified as an unapproved compound within the research context described here. No outcome data, efficacy findings, or safety results have been posted for this trial as of this update.
Details on trial design, enrollment criteria, and further study information are available through the official registration at ClinicalTrials.gov under the identifier NCT06821100. Readers seeking more background on this compound can consult the compound overview for additional context.